Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
Pregabalin Phase 2 Results Expected
Pregabalin • Diabetic Peripheral Neuropathic Pain
Target Indication
Diabetic Peripheral Neuropathic Pain
Clinical Trial
NCT06619860Last updated: 12/3/2025
Pregabalin Viatris Pharma (previously Pregabalin Pfizer)
Neuropathic painPregabalin Viatris Pharma is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Pregabalin Viatris Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised Anxiety Disorder Pregabalin Viatris Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
View on EMALyrica
Neuropathic pain Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults. Epilepsy Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Generalised anxiety disorder Lyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
View on EMA